20017-68-9

Basic information

• Product Name: 1-BROMO-3,3-DIPHENYLPROPANE
• Synonyms: 1,1'-(3-bromopropylidene)bisbenzene;1,1'-(3-Brompropylidene)bisbenzene;1-BROMO-3,3-DIPHENYLPROPANE 99%;(1-Phenyl-3-bromopropyl)benzene;1,1-Diphenyl-3-bromopropane;1-Bromo-3,3-diphenylpropane,99%;BroMo-3,3-diphenylpropan;3-broMo-1,1-diphenylpropane,1-broMo-3,3-diphenylpropane
• CAS NO: 20017-68-9
• Molecular Formula: C₁₅H₁₅Br
• Molecular Weight: 275.18
• EINECS: 243-467-8
• Product Categories: Propanes/propenes
• Mol File: 20017-68-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 39-42 °C
• Boiling Point: 145°C 2mm
• Flash Point: 143.2°C
• Appearance: White to off-white/Crystalline Powder
• Density: 1.3288 (rough estimate)
• Vapor Pressure: 0.000719mmHg at 25°C
• Refractive Index: 1.6822 (estimate)
• Storage Temp.: 0-10°C
• Solubility: soluble in Methanol
• CAS DataBase Reference: 1-BROMO-3,3-DIPHENYLPROPANE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BROMO-3,3-DIPHENYLPROPANE(20017-68-9)
• EPA Substance Registry System: 1-BROMO-3,3-DIPHENYLPROPANE(20017-68-9)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 45-36/37/39-26
• RIDADR: UN3261
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 20017-68-9(Hazardous Substances Data)

Usage

Chemical Properties

white to off-white crystalline powder

InChI:InChI=1/C15H15Br/c16-12-11-15(13-7-3-1-4-8-13)14-9-5-2-6-10-14/h1-10,15H,11-12H2

Upstream product

• 29636-75-7 3-bromo-1-phenylpropan-1-one 
• 71-43-2 benzene 
• 7476-18-8 3,3-diphenyl-propionic acid ethyl ester 
• 606-83-7 3,3-Diphenylpropionic acid 
• 23426-03-1 3,3-diphenylpropanoic acid methyl ester 
• 3461-34-5 methyl 3,3-diphenylacrylate 
• 119-61-9 benzophenone 
• 20017-67-8 3,3-diphenylpropan-1-ol 
• 300-57-2 allylbenzene 

Downstream Products

• 240486-15-1 8-(3,3-diphenylpropyl)-1,4-dioxa-8-azaspiro[4.5]decane 
• 145722-89-0 4,4-diphenylbutylamine maleate 
• 145533-02-4 N-(4,4-diphenylbutyl)-2-phenylethylamine 

Relevant articles and documents

Pyridyl-Acyl Hydrazone Rotaxanes and Molecular Shuttles

We report on rotaxanes featuring a pyridyl-acyl hydrazone moiety on the axle as a photo/thermal-switchable macrocycle binding site. The pyridyl-acyl E-hydrazone acts as a hydrogen bonding template that directs the assembly of a benzylic amide macrocycle around the axle to form [2]rotaxanes in up to 85% yield; the corresponding Z-hydrazone thread affords no rotaxane under similar conditions. However, the E-rotaxane can be smoothly converted into the Z-rotaxane in 98% yield under UV irradiation. The X-ray crystal structures of the E- and Z-rotaxanes show different intercomponent hydrogen bonding patterns. In molecular shuttles containing pyridyl-acyl hydrazone and succinic amide ester binding sites, the change of position of the macrocycle on the thread can be achieved through a series of light irradiation and heating cycles with excellent positional integrity (>95%) and switching fidelity (98%) in each state.

Hydrogenated acridine derivative and its application

The invention relates to the field of chemical synthesis, and particularly relates to a compound with the general formula being Y-L-X and an application of the compound serving as a calcium channel blocking agent or/and an acetylcholinesterase inhibitor. The compound with the general formula being Y-L-X can be used for adjusting calcium homeostasis and treating cardiovascular diseases, stroke or dementia.

Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects

The recent discovery that small molecule ligands for the peptidyl-prolyl isomerase (PPIase) FKBP12 possess powerful neuroprotective and neuroregenerative properties in vitro and in vivo suggests therapeutic utility for such compounds in neurodegenerative disease. The neurotrophic effects of these compounds are independent of the immunosuppressive pathways by which drugs such as FK506 and rapamycin operate. Previous work by ourselves and other groups exploring the structure-activity relationships (SAR) of small molecules that mimic only the FKBP binding domain portion of FK506 has focused on esters of proline and pipecolic acid. We have explored amide and thioester analogues of these earlier structures and found that they too are extremely potent in promoting recovery of lesioned dopaminergic pathways in a mouse model of Parkinson's disease. Several compounds were shown to be highly effective upon oral administration after lesioning of the dopaminergic pathway, providing further evidence of the potential clinical utility of a variety of structural classes of FKBP12 ligands.